Dermapharm Holding SE

XETRA DMP.DE

Dermapharm Holding SE Goodwill for the year ending December 31, 2023: USD 638.54 M

Dermapharm Holding SE Goodwill is USD 638.54 M for the year ending December 31, 2023, a 119.96% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.
  • Dermapharm Holding SE Goodwill for the year ending December 31, 2022 was USD 290.30 M, a -3.67% change year over year.
  • Dermapharm Holding SE Goodwill for the year ending December 31, 2021 was USD 301.36 M, a -7.35% change year over year.
  • Dermapharm Holding SE Goodwill for the year ending December 31, 2020 was USD 325.27 M, a 43.31% change year over year.
  • Dermapharm Holding SE Goodwill for the year ending December 31, 2019 was USD 226.96 M, a 263.07% change year over year.
Key data
Date Goodwill Total Assets Current Liabilities Total Non-Current Liabilities
Market news
Loading...
XETRA: DMP.DE

Dermapharm Holding SE

CEO Dr. Hans-Georg Feldmeier
IPO Date April 12, 2018
Location Germany
Headquarters Lil-Dagover-Ring 7
Employees 3,603
Sector Health Care
Industries
Description

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

StockViz Staff

January 15, 2025

Any question? Send us an email